Effectiveness of different therapeutic strategies in preventing diverticulitis recurrence

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 3, 2013, Pages 342-348

  Tursi, A ^a   Elisei, W ^b   Giorgetti, G M ^c   Inchingolo, C D ^d   Nenna, R ^d   Picchio, M ^e   Maiorano, M ^d   Penna, A ^f   Lecca, P G ^g   Brandimarte, G ^g  

^a ASL BAT   (Italy)

^b ASL Roma H   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

^d Lorenzo Bonomo Hospital   (Italy)

^e Hospital P Colombo   (Italy)

^f Division of Gastroenterology   (Italy)

^g Cristo Re Hospital   (Italy)

Author keywords

Acute uncomplicated diverticulitis; Endoscopy; Follow up; Histology; Mesalazine; Recurrence; Rifaximin

Indexed keywords

MESALAZINE; RIFAXIMIN;

ACUTE UNCOMPLICATED DIVERTICULITIS; ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; DIVERTICULITIS; DRUG EFFICACY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINE ENDOSCOPY; MAJOR CLINICAL STUDY; MALE; RECURRENT DISEASE; REMISSION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIVERTICULITIS, COLONIC; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RIFAMYCINS; TIME FACTORS;

EID: 84878622130     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. SHETH AA, LONGO W, FLOCH MH. Diverticular disease and diverticulitis. Am J Gastroenterol 2008; 103: 1550-1556.
2. TURSI A. New physiopathological and therapeutic approaches to diverticular disease of the colon. Expert Opin Pharmacother 2007; 8: 299-307.
3. TURSI A, BRANDIMARTE G, GIORGETTI G, ELISEI W, MAIORANO M, AIELLO F. The clinical picture of uncomplicated versus complicated diverticulitis of the colon. Dig Dis Sci 2008; 53: 2474-2479.
4. TURSI A, PAPAGRIGORIADIS S. Review article: the current and evolving treatment of colonic diverticular disease. Aliment Pharmacol Ther 2009; 30: 532-546.
5. TURSI A, BRANDIMARTE G, DAFFINÀ R. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Dig Liver Dis 2002; 34: 510-515.
6. DI MARIO F, ARAGONA G, LEANDRO G, COMPARATO G, FANIGLIULO L, CAVALLARO LG, CAVESTRO GM, IORI V, MAINO M, MOUSSA AM, GNOCCHI A, MAZZOCCHI G, FRANZÉ A. Efficacy of mesalazine in the treatment of symptomatic diverticular disease. Dig Dis Sci 2005; 50: 581-586.
7. TURSI A. Diverticular disease: what is the best long-term treatment? Nat Rev Gastroenterol Hepatol 2010; 7: 77-78.
8. ZULLO A, HASSAN C, MACONI G, MANES G, TAMMARO G, DE FRANCESCO V, ANNIBALE B, FICANO L, BURI L, GATTO G, LORENZETTI R, CAMPO SM, IERARDI E, PACE F, MORINI S. Cyclic antibiotic therapy for diverticular disease: a critical reappraisal. J Gastrointestin Liver Dis 2010; 19: 295-302.
9. MACONI G, BARBARA G, BOSETTI C, CUOMO R, ANNIBALE B. Treatment of diverticular disease of the colon and prevention of acute diverticulitis: a systematic review. Dis Colon Rectum 2011; 54: 1326-1338.
10. TURSI A, BRANDIMARTE G, ELISEI W, GIORGETTI GM, INCHINGOLO CD, DANESE S, AIELLO F. Assessment and grading of mucosal inflammation in colonic diverticular disease. J Clin Gastroenterol 2008; 42: 699-703.
11. TURSI A, BRANDIMARTE G, ELISEI W, GIORGETTI GM, INCHINGOLO CD, AIELLO F. Faecal calprotectin in colonic diverticular disease: a case-control study. Int J Colorectal Dis 2009; 24: 49-55.
12. SANDLER RS, EVERHART JE, DONOWITZ M, ADAMS E, CRONIN K, GOODMAN C, GEMMEN E, SHAH S, AVDIC A, RUBIN R. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122: 1500-1511.
13. RUFFOLO C, SCARPA M, FAGGIAN D, BASSO D, D'INCÀ R, PLEBANI M, STURNIOLO GC, BASSI N, ANGRIMAN I. Sub-clinical intestinal inflammation in patients with Crohn's disease following bowel resection: a smoldering fire. J Gastrointest Surg 2010; 14: 24-31.
14. BRODERICK-VILLA G, BURCHETTE RJ, COLLINS JC, ABBAS MA, HAIGH PI. Hospitalization for acute diverticulitis does not mandate routine elective colectomy. Arch Surg 2005; 140: 576-581
15. KÄSER SA, FANKHAUSER G, GLAUSER PM, TOIA D, MAURER CA. Diagnostic value of inflammation markers in predicting perforation in acute sigmoid diverticulitis. World J Surg 2010; 34: 2717-2722.
16. ANAYA DA, FLUM DR. Risk of emergency colectomy and colostomy in patients with diverticular disease. Arch Surg 2005; 140: 681-685.
17. LATELLA G, PIMPO MT, SOTTILI S, ZIPPI M, VISCIDO A, CHIARAMONTE M, FRIERI G. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 2003; 18: 55-62.
18. LATELLA G, SCARPIGNATO C. Rifaximin in the management of colonic diverticular disease. Expert Rev Gastroenterol Hepatol 2009; 3: 585-598.
19. GATTA L, VAKIL N, VAIRA D, PILOTTO A, CURLO M, COMPARATO G, LEANDRO G, FERRO U, LERA M, MILLETTI S, DI MARIO F. Efficacy of 5-ASA in the treatment of colonic diverticular disease. J Clin Gastroenterol 2010; 44: 113-119.
20. TURSI A, BRANDIMARTE G, GIORGETTI GM, ELISEI W. Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon. Hepato-gastroenterol 2008; 55: 916-920.
21. ODZE R, ANTONIOLI D, PEPPERCORN M, GOLDMAN H. Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis. Am J Surg Pathol 1993; 17: 869-875.
22. SCARPIGNATO C, PELOSINI I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006; 73(Suppl. 1): 15-38.
23. JOLLEY J. High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome. Clin Exp Gastroenterol 2011; 4: 43-48.
24. PRANTERA C, LOCHS H, CAMPIERI M, SCRIBANO ML, STURNIOLO GC, CASTIGLIONE F, COTTONE M. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006; 23: 1117-1125.
25. SHAFRAN I, BURGUNDER P. Adjunctive antibiotic therapy with rifaximin may help reduce Crohn's disease activity. Dig Dis Sci 2010; 55: 1079-1084.
26. TURSI A, ELISEI W, GIORGETTI GM, LECCA PG, PAPA A, BRANDIMARTE G. Persistence of endoscopic and histological inflammation are risk factors of diverticulitis recurrence after attack of acute uncomplicated diver ticulitis. Gastroenterology 2011; 140(Suppl. 1): S-61.
27. TURSI A, BRANDIMARTE G, ELISEI W, GIORGETTI GM, INCHINGOLO CD, AIELLO F. Effect of mesalazine on epithelial cell proliferation in colonic diverticular disease. Dig Liver Dis 2008; 40: 737-742.
28. MORINI S, HASSAN C, ZULLO A, DE FRANCESCO V, BURATTINI O, MARGIOTTA M, PANELLA C, IERARDI E. Epithelial cell proliferation of the colonic mucosa in diverticular disease: a case-control study. Aliment Pharmacol Ther 2005; 21: 1385-1390.
29. SZOJDA MM, CUESTA MA, MULDER CM, FELT-BERSMA RJF. Review article: management of diverticulitis. Aliment Pharmacol Ther 2007; 26(Suppl. 2): 67-76.
30. JACOBS DO. Clinical practice. Diverticulitis. N Engl J Med 2007; 357: 2057-2066.
31. LAHAT A, YANAI H, MENACHEM Y, AVIDAN B, BAR-MEIR S. The feasibility and risk of early colonoscopy in acute diverticulitis: a prospective controlled study. Endoscopy 2007; 39: 521-524.
32. HJERN F, JONAS E, HOLMSTRÖM B, JOSEPHSON T, MELLGREN A, JOHANSSON C. CT colonography versus colonoscopy in the follow-up of patients after diverticulitis-a prospective, comparative study. Clin Radiol 2007; 62: 645-650.
33. HALE WB; NDSG. Colonoscopy in the diagnosis and management of diverticular disease. J Clin Gastroenterol 2008; 42: 1142-1144.